Literature DB >> 17981909

A quantum mechanic/molecular mechanic study of the wild-type and N155S mutant HIV-1 integrase complexed with diketo acid.

Cláudio Nahum Alves1, Sergio Martí, Raquel Castillo, Juan Andrés, Vicent Moliner, Iñaki Tuñón, Estanislao Silla.   

Abstract

Integrase (IN) is one of the three human immunodeficiency virus type 1 (HIV-1) enzymes essential for effective viral replication. Recently, mutation studies have been reported that have shown that a certain degree of viral resistance to diketo acids (DKAs) appears when some amino acid residues of the IN active site are mutated. Mutations represent a fascinating experimental challenge, and we invite theoretical simulations for the disclosure of still unexplored features of enzyme reactions. The aim of this work is to understand the molecular mechanisms of HIV-1 IN drug resistance, which will be useful for designing anti-HIV inhibitors with unique resistance profiles. In this study, we use molecular dynamics simulations, within the hybrid quantum mechanics/molecular mechanics (QM/MM) approach, to determine the protein-ligand interaction energy for wild-type and N155S mutant HIV-1 IN, both complexed with a DKA. This hybrid methodology has the advantage of the inclusion of quantum effects such as ligand polarization upon binding, which can be very important when highly polarizable groups are embedded in anisotropic environments, for example in metal-containing active sites. Furthermore, an energy terms decomposition analysis was performed to determine contributions of individual residues to the enzyme-inhibitor interactions. The results reveal that there is a strong interaction between the Lys-159, Lys-156, and Asn-155 residues and Mg(2+) cation and the DKA inhibitor. Our calculations show that the binding energy is higher in wild-type than in the N155S mutant, in accordance with the experimental results. The role of the mutated residue has thus been checked as maintaining the structure of the ternary complex formed by the protein, the Mg(2+) cation, and the inhibitor. These results might be useful to design compounds with more interesting anti-HIV-1 IN activity on the basis of its three-dimensional structure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981909      PMCID: PMC2267120          DOI: 10.1529/biophysj.107.107623

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  62 in total

Review 1.  HIV integrase structure and function.

Authors:  D Esposito; R Craigie
Journal:  Adv Virus Res       Date:  1999       Impact factor: 9.937

2.  4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells.

Authors:  J S Wai; M S Egbertson; L S Payne; T E Fisher; M W Embrey; L O Tran; J Y Melamed; H M Langford; J P Guare; L Zhuang; V E Grey; J P Vacca; M K Holloway; A M Naylor-Olsen; D J Hazuda; P J Felock; A L Wolfe; K A Stillmock; W A Schleif; L J Gabryelski; S D Young
Journal:  J Med Chem       Date:  2000-12-28       Impact factor: 7.446

Review 3.  Accommodating protein flexibility in computational drug design.

Authors:  H A Carlson; J A McCammon
Journal:  Mol Pharmacol       Date:  2000-02       Impact factor: 4.436

4.  The Cationminus signpi Interaction.

Authors:  Jennifer C. Ma; Dennis A. Dougherty
Journal:  Chem Rev       Date:  1997-08-05       Impact factor: 60.622

5.  HIV-1 integrase catalytic core: molecular dynamics and simulated fluorescence decays.

Authors:  C Laboulais; E Deprez; H Leh; J F Mouscadet; J C Brochon; M Le Bret
Journal:  Biophys J       Date:  2001-07       Impact factor: 4.033

6.  Ordered water and ligand mobility in the HIV-1 integrase-5CITEP complex: a molecular dynamics study.

Authors:  H Ni; C A Sotriffer; J A McCammon
Journal:  J Med Chem       Date:  2001-09-13       Impact factor: 7.446

7.  Structural determinants for HIV-1 integrase inhibition by beta-diketo acids.

Authors:  Christophe Marchand; Xuechun Zhang; Godwin C G Pais; Kiriana Cowansage; Nouri Neamati; Terrence R Burke; Yves Pommier
Journal:  J Biol Chem       Date:  2002-01-22       Impact factor: 5.157

8.  Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.

Authors:  D J Hazuda; P Felock; M Witmer; A Wolfe; K Stillmock; J A Grobler; A Espeseth; L Gabryelski; W Schleif; C Blau; M D Miller
Journal:  Science       Date:  2000-01-28       Impact factor: 47.728

Review 9.  HIV-1 integrase: structural organization, conformational changes, and catalysis.

Authors:  E Asante-Appiah; A M Skalka
Journal:  Adv Virus Res       Date:  1999       Impact factor: 9.937

10.  Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design.

Authors:  Y Goldgur; R Craigie; G H Cohen; T Fujiwara; T Yoshinaga; T Fujishita; H Sugimoto; T Endo; H Murai; D R Davies
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

View more
  4 in total

1.  Homology modeling, molecular dynamics and QM/MM study of the regulatory protein PhoP from Corynebacterium pseudotuberculosis.

Authors:  Gleiciane Moraes; Vasco Azevedo; Marcília Costa; Anderson Miyoshi; Artur Silva; Vivian da Silva; Diana de Oliveira; Maria Fátima Teixeira; Jerônimo Lameira; Cláudio Nahum Alves
Journal:  J Mol Model       Date:  2011-06-24       Impact factor: 1.810

2.  Computational analysis of aspartic protease plasmepsin II complexed with EH58 inhibitor: a QM/MM MD study.

Authors:  Natália de Farias Silva; Jerônimo Lameira; Cláudio Nahum Alves
Journal:  J Mol Model       Date:  2011-01-25       Impact factor: 1.810

3.  Binding modes of diketo-acid inhibitors of HIV-1 integrase: a comparative molecular dynamics simulation study.

Authors:  Meilan Huang; Guy H Grant; W Graham Richards
Journal:  J Mol Graph Model       Date:  2011-04-09       Impact factor: 2.518

Review 4.  Quantum mechanics implementation in drug-design workflows: does it really help?

Authors:  Olayide A Arodola; Mahmoud Es Soliman
Journal:  Drug Des Devel Ther       Date:  2017-08-31       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.